Managing Treatment-Related Toxicities in EGFR-Mutant NSCLC

This segment focuses on the real-world management of treatment-related toxicities in EGFR-mutant non-small cell lung cancer (NSCLC). Drs. Mark Socinski and Susan Scott discuss the multidisciplinary strategies used to mitigate adverse events associated with combination therapies, emphasizing that proactive supportive care can lessen, but not completely eliminate, treatment-related toxicities. They review evidence-based prophylactic measures for managing dermatologic adverse events, including topical antibiotics, ceramide-based moisturizers, scalp-directed therapies, and chlorhexidine for paronychia prevention. The conversation also addresses the practical challenges of anticoagulation management for venous thromboembolism (VTE) prophylaxis, including the current recommendation to discontinue anticoagulation after four months despite ongoing concerns about persistent thromboembolic risk in patients with lung cancer. Together, they highlight the importance of patient education, adherence to supportive care measures, and individualized toxicity management to optimize treatment outcomes.